Using genetics to understand why acute myeloid leukaemia cells don’t respond to treatment
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
Using existing drugs in a new way to treat high-risk acute lymphoblastic leukaemia
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
Can radiotherapy near the spleen lead to severe infections later in life?
Looking into whether survivors of childhood cancer are at risk of severe infections.
Investigating how regulatory regions of the genome communicate with cancer causing genes
Finding which regulatory regions of the genome are causing leukaemia by acting on the wrong gene
New treatments for relapsed rhabdomyosarcoma
Developing better models of rhabdomyosarcoma to test available treatments.
Paediatric Hepatic International Tumour Trial
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
Developing less toxic therapies for children with acute lymphoblastic leukaemia
Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.
Accelerating drugs into clinical trials for patients with Ewing sarcoma
Ewing sarcoma is the second most common bone tumour in young people. The primary goal of this project is to fast-track a targeted drug combination for evaluation in clinical trials, with the aim of improving outcomes and minimising treatment associated morbidities for Ewing sarcoma patients.